文献速递性腺与生殖内分泌垂体与肾上腺疾病骨质疏松与钙磷/甲状旁腺

阿片类药物与下丘脑-垂体-性腺(HPG)轴

Opioids and the Hypothalamic-Pituitary-Gonadal (HPG) Axis.
PubMed 文献 · J Clin Endocrinol Metab · 2020-01-01

本文综述阿片类药物所致性腺功能减退(OIH)的患病率、后果与处理。近期系统综述报告患病率为69%,研究间异质性大,与阿片类型、剂量及使用时长相关。OIH可致性功能障碍、抑郁、生活质量下降及骨密度降低;男性睾酮替代治疗(TRT)研究结果不一,女性研究更少。作者提出对使用阿片者应告知风险、筛查症状并在长期使用>3个月时检测性激素,确诊且临床需要时予性激素治疗。

要点

  • 近期系统综述报告OIH患病率为69%,研究间异质性大。
  • OIH后果包括性功能障碍、抑郁、生活质量下降及骨密度降低。
  • 男性OIH的TRT随机对照试验缺乏且结果不一,女性研究更少。

核心结论

  • OIH患病率高但仍被低估和治疗不足,可致多种内分泌与代谢后果。

研究设计与样本

  • 检索PubMed截至2019年12月的英文文献,主题为阿片类药物与性腺功能减退,并检索所获文献的参考文献。

主要发现

  • 近期系统综述报告OIH患病率为69%。
  • 研究间异质性大,特定阿片类型、较高剂量和较长使用时长与性腺功能减退关联更强。
  • OIH后果包括性功能障碍、抑郁、生活质量下降和骨密度降低。
  • 男性OIH的TRT随机对照试验缺乏,女性OIH治疗研究更少。
  • 男性TRT研究结果不一,部分研究支持TRT对某些指标有益,另一些未显示明确获益。

关键数值与推荐

  • 长期使用阿片类药物>3个月时应筛查性腺功能减退症状并检测性激素水平。
  • 若计划继续慢性阿片治疗≥6个月,对确诊性腺功能减退且临床需要者予性激素治疗。

临床怎么用

  • 对使用阿片类药物的患者应告知该并发症及其潜在后果。
  • 长期使用阿片类药物>3个月者筛查性腺功能减退的症状和体征,随后检测性激素水平。
  • 对确诊性腺功能减退且临床需要者,若计划继续慢性阿片治疗≥6个月,予性激素治疗。

局限性

  • 研究间存在很大异质性。
  • 评估男性OIH的TRT疗效的随机对照试验缺乏。
  • 女性OIH治疗的研究更少。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: Hypogonadism is a well-established consequence of opioid use. It has been reported in both men and women, although more widely studied in men. EVIDENCE ACQUISITION: PubMed was searched for articles in English until December 2019 for opioids and hypogonadism. Bibliography of retrieved articles was searched for relevant articles. EVIDENCE SYNTHESIS: The prevalence of opioid-induced hypogonadism (OIH) varies between studies but was reported to be 69% in a recent systematic review. There is large heterogeneity in the studies, with different factors shown to have stronger association with hypogonadism such as specific types of opioids, higher doses, and longer durations of use. The consequences of OIH include sexual dysfunction, depression, decreased quality of life, and low bone density. There is paucity of randomized controlled trials assessing the efficacy of testosterone replacement therapy (TRT) for OIH in men, and even less studies on treating OIH in women. TRT studies in men reported varying outcomes with some studies favoring and others showing no clear benefit of TRT on different measures. CONCLUSIONS: Despite the high prevalence of OIH, it remains underrecognized and undertreated with multiple endocrine and metabolic consequences. A reasonable approach in patients using opioids includes informing them of this complication and its potential consequences, screening for signs and symptoms of hypogonadism then sex hormone levels if prolonged opioid use > 3 months, and treating patients diagnosed with hypogonadism, if and when clinically indicated, with sex hormones if chronic opioids are planned to be continued for ≥ 6 months.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Wehbeh L, Dobs AS. Opioids and the Hypothalamic-Pituitary-Gonadal (HPG) Axis. J Clin Endocrinol Metab. 2020. PMID: 32770254. doi:10.1210/clinem/dgaa417

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。